Clinical Trials Browser

Phase 2/3 × Unknown × INDUSTRY × Clear all

NCT03721744 2024-04-03

A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer

Phase 2/3 Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT03500380 2024-02-20

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Phase 2/3 Unknown

Breast Diseases, Breast Neoplasms

NCT05673512 2024-02-20

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer

Phase 2/3 Unknown

HER2 Gene Mutation

NCT04560894 2024-02-01

HCC

Phase 2/3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Phase 2/3 Unknown

Nasopharyngeal Carcinoma

NCT05802342 2023-04-06

A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer

Phase 2/3 Unknown

To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients

NCT04924699 2023-03-17

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 2/3 Unknown

Breast Neoplasms

NCT05661240 2022-12-22

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03086993 2022-03-24

Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Phase 2/3 Unknown

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT00003338 2021-08-16

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Phase 2/3 Unknown

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03008148 2021-05-11

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM

Phase 2/3 Unknown

Glioblastoma

NCT04874844 2021-05-10

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

Phase 2/3 Unknown

NSCLC

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

Nonsquamous Non-small Cell Lung Cancer

NCT04737967 2021-02-04

The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy

Phase 2/3 Unknown

Cancer Pain

NCT03794440 2021-01-22

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Phase 2/3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT03288870 2020-10-29

DOMINUS

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04435652 2020-06-17

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Phase 2/3 Unknown

Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT03592706 2020-04-16

Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

Phase 2/3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03873532 2020-02-13

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Phase 2/3 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT04254471 2020-02-05

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Phase 2/3 Unknown

Small Cell Lung Carcinoma

NCT04206254 2019-12-20

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer

Phase 2/3 Unknown

Gastrointestinal

Liver Neoplasms

NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Phase 2/3 Unknown

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT02461407 2017-12-29

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

Phase 2/3 Unknown

Gastrointestinal

Stomach Neoplasms

NCT02449343 2017-04-25

Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

Phase 2/3 Unknown

Sarcoma

NCT02029209 2016-12-16

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01729663 2015-09-02

Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients

Phase 2/3 Unknown

Melanoma

NCT02510118 2015-08-03

Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients

Phase 2/3 Unknown

Gastrointestinal

Colonic Neoplasms

NCT00295802 2014-02-07

Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer

Phase 2/3 Unknown

Prostatic Neoplasms

NCT01277172 2011-01-14

TREND

Phase 2/3 Unknown

Immunoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

NCT00043576 2009-03-12

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

Phase 2/3 Unknown

Prostatic Neoplasms